Synergistic enhancement by interleukin-1 alpha of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ mice (Q72852185)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8339383%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

title

Synergistic enhancement by interleukin-1 alpha of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ mice (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8339383%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

author name string

C S Johnson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8339383%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

M J Chang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8339383%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

W D Yu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8339383%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

R A Modzelewski

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8339383%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

J R Grandis

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8339383%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

D R Vlock

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8339383%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

P Furmanski

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8339383%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

publication date

1 January 1993

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8339383%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

29 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8339383%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8339383%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8339383%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

page(s)

339-346

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8339383%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf00735916

29 October 2019

exact match

0 references

cites work

Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review

1 reference

12 December 2020

Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin

1 reference

12 December 2020

Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1 alpha

1 reference

12 December 2020

Interleukin 1 is a radioprotector

1 reference

12 December 2020

The effect of adrenalectomy and dexamethasone on interleukin-1 alpha induced responses in RIF-1 tumours

1 reference

12 December 2020

An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor-alpha increases neutrophil adherence by a CDw18-dependent mechanism

1 reference

12 December 2020

1 reference

12 December 2020

Effect of dexamethasone on vascular function in RIF-1 tumors

1 reference

12 December 2020

Combination effect of recombinant human interleukin 1 alpha with antitumor drugs on syngeneic tumors in mice

1 reference

12 December 2020

Synergistic antitumor activity of etoposide and human interleukin-1 alpha against human melanoma cells.

1 reference

12 December 2020

Toxic effects of cis-dichlorodiammineplatinum(II) in man.

1 reference

12 December 2020

Combination therapy with adriamycin and interleukin 2 augments immunity against murine renal cell carcinoma

1 reference

12 December 2020

Augmented antitumor effect of recombinant human interleukin-1 alpha by indomethacin

1 reference

12 December 2020

In vivo effects of recombinant human and murine interleukin-1 alpha (IL-1 alpha) on murine hematopoiesis

1 reference

12 December 2020

Potentiation of the T-lymphocyte response to mitogens. I. The responding cell

1 reference

12 December 2020

Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor

1 reference

12 December 2020

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

12 December 2020

31P-nuclear magnetic resonance studies of the effect of recombinant human interleukin 1 alpha on the bioenergetics of RIF-1 tumors

1 reference

12 December 2020

Antitumor effect of recombinant human interleukin 1 alpha against murine syngeneic tumors

1 reference

12 December 2020

Preliminary report: effects of interleukin-1 on platelet counts

1 reference

12 December 2020

Human interleukin 1 is a cytocidal factor for several tumor cell lines.

1 reference

12 December 2020

Interleukin 1-induced, T cell-mediated regression of immunogenic murine tumors. Requirement for an adequate level of already acquired host concomitant immunity

1 reference

12 December 2020

Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities

1 reference

12 December 2020

In vivo inhibition of tumor growth of B16 melanoma by recombinant interleukin 1 beta. I. Tumor inhibition parallels lymphocyte-activating factor activity of interleukin 1 beta proteins

1 reference

12 December 2020

Both a monoclonal antibody and antisera specific for determinants unique to individual cloned helper T cell lines can substitute for antigen and antigen-presenting cells in the activation of T cells

1 reference

12 December 2020

Enhancement of natural killer cytotoxicity by cis-diamminedichloroplatinum (II) in vivo and in vitro.

1 reference

12 December 2020

Potentiation of interleukin 1 alpha mediated antitumor effects by ketoconazole.

1 reference

12 December 2020

An endotoxin-induced serum factor that causes necrosis of tumors

1 reference

12 December 2020

Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands

1 reference

12 December 2020

In vivo effects of interleukin-1 alpha on regenerating mouse bone marrow myeloid colony-forming cells after treatment with 5-fluorouracil

1 reference

12 December 2020

Acute hemorrhagic necrosis of tumors induced by interleukin-1 alpha: effects independent of tumor necrosis factor

1 reference

12 December 2020

Synergistic Cytotoxicity of Recombinant Human TNF and Various Anti-Cancer Drugs

1 reference

12 December 2020

Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro.

1 reference

12 December 2020

Interleukin-1 accelerates murine granulocyte recovery following treatment with cyclophosphamide

1 reference

12 December 2020

Synergy of interleukin 1 and granulocyte colony-stimulating factor: in vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice

1 reference

12 December 2020

Interleukin 1 is more than an interleukin

1 reference

12 December 2020

Antitumor effects of recombinant human interleukin 1 alpha in RIF-1 and Panc02 solid tumors

1 reference

12 December 2020

There is more than one interleukin 1.

1 reference

12 December 2020

A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer

1 reference

12 December 2020

Natural and recombinant human interleukin 1-beta is cytotoxic for human melanoma cells

1 reference

12 December 2020

Cytokines and endothelial cell biology

1 reference

12 December 2020

Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II.

1 reference

12 December 2020

A new mouse tumor model system (RIF-1) for comparison of end-point studies

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00735916

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8339383%20AND%20SRC:MED&resulttype=core&format=json

29 October 2019

1 reference